SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Evofem
Biosciences, Inc. (NASDAQ: EVFM) announced today that members of
management will participate in a Virtual Investor KOL Roundtable on
Thursday, October 29, 2020 at
2:00 p.m. ET.
Saundra Pelletier, Chief
Executive Officer, and Kelly
Culwell, M.D., Chief Medical Officer of Evofem Biosciences
will be joined for the Roundtable by renowned women's reproductive
health thought leader Patricia Cason,
RN, MS, FNP-BC who will provide insights on the current
birth control landscape and contraceptive counseling.
Ms. Cason is a family nurse practitioner, published author, and
educator with a specialty in sexual and reproductive health.
Ms. Cason has practiced for 38 years in a wide variety of clinical
and academic settings and is a contracted consultant to training
agencies, non-profits, and state departments of health across the
United States. She is an editor of the 21st Edition of
Contraceptive Technology for which she wrote a seminal
chapter on reproductive goals and contraception
counseling.
A live video webcast of the KOL Roundtable will be
available on the Events page of the Investors section of
the Company's website, www.evofem.com. A webcast replay will
be available two hours following the live presentation and will be
accessible for three months.
In addition to the KOL Roundtable discussion, members of the
Evofem management team will be available for one-on-one meetings
with qualified members of the investment community. To schedule a
one-on-one call with management, please submit a request through
the conference website, virtualinvestorco.com, or by email to
info@virtualinvestorco.com. For more information about the event,
please visit virtualinvestorco.com.
About Evofem Biosciences, Inc.
Evofem Biosciences,
Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical
company committed to developing and commercializing innovative
products to address unmet needs in women's sexual and reproductive
health, including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi™ (lactic acid,
citric acid and potassium bitartrate), is the first and only
hormone-free, prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company is
evaluating EVO100 in a Phase 3 clinical
trial, 'EVOGUARD,' for the prevention of urogenital
Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490.3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-virtual-investor-kol-roundtable-301159513.html
SOURCE Evofem Biosciences, Inc.